However, resistance to these treatments inevitably occurs [42], hinting that targeting the AR pathway might not be sufficient, especially given the idea that increased crosstalk between distinct signaling pathways causes activation of AR target genes and regulatory networks in advanced prostate cancer [8, 9]. This evidence concerns the gene AR and prostate cancer.